Leerink Partnrs Has Positive Outlook for Cencora Q3 Earnings

Cencora, Inc. (NYSE:COR - Free Report) - Analysts at Leerink Partnrs increased their Q3 2025 earnings estimates for shares of Cencora in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $3.89 per share for the quarter, up from their previous forecast of $3.87. The consensus estimate for Cencora's current full-year earnings is $15.36 per share. Leerink Partnrs also issued estimates for Cencora's FY2025 earnings at $15.52 EPS, FY2026 earnings at $17.17 EPS and FY2027 earnings at $19.01 EPS.

Several other research analysts have also recently weighed in on the company. UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Robert W. Baird boosted their target price on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $277.90.

Cencora Price Performance

COR stock traded down $0.29 during trading on Friday, hitting $246.10. The stock had a trading volume of 445,888 shares, compared to its average volume of 1,450,955. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53. Cencora has a twelve month low of $214.77 and a twelve month high of $262.26. The stock has a market capitalization of $47.57 billion, a P/E ratio of 34.94, a PEG ratio of 1.49 and a beta of 0.49. The company's 50-day moving average price is $238.94 and its two-hundred day moving average price is $236.90.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%.

Institutional Trading of Cencora

A number of large investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of Cencora during the fourth quarter worth $19,543,000. Sei Investments Co. increased its position in shares of Cencora by 5.2% during the fourth quarter. Sei Investments Co. now owns 321,877 shares of the company's stock worth $72,319,000 after acquiring an additional 16,039 shares during the period. American Century Companies Inc. grew its stake in shares of Cencora by 43.8% during the fourth quarter. American Century Companies Inc. now owns 862,637 shares of the company's stock worth $193,818,000 after purchasing an additional 262,823 shares in the last quarter. Mizuho Securities USA LLC grew its stake in shares of Cencora by 46.9% during the fourth quarter. Mizuho Securities USA LLC now owns 16,621 shares of the company's stock worth $3,734,000 after purchasing an additional 5,309 shares in the last quarter. Finally, Sciencast Management LP acquired a new position in shares of Cencora during the fourth quarter worth $243,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. This represents a 6.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock valued at $17,790,912 over the last quarter. 10.80% of the stock is owned by company insiders.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora's payout ratio is 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.